Transforming Wound Healing Through Innovation
Harnessing Immune Based Healing
Oridivus is pioneering a first-in-class drug-device combination therapy for oral mucosa wound healing. Our breakthrough technology delivers targeted treatment through electrospun nanofibers, offering faster healing and reduced pain for patients in dental and oral surgery.
Our Mission
To develop advanced biomaterial therapies that harness the body's natural healing capacity to predictably accelerate mucosal tissue repair and reduce pain.
1
Discovery
Pioneering electrospun nanofiber technology for controlled drug delivery to oral mucosa wounds
2
Development
Formulating ORD002 with FTY720 for 48-72 hour sustained release over wound sites
3
Regulatory Path
Advancing through FDA 505(b)(2) pathway for accelerated approval and market entry
4
Clinical Translation
Targeting gingival grafts as our first indication in dental and oral surgery
Introducing ORD002
ORD002 is a first-in-class drug-device combination product that represents a paradigm shift in oral mucosa wound healing. By loading FTY720 (fingolimod) onto bioengineered electrospun nanofiber scaffolds, we deliver precise, sustained therapy directly to the wound site.
First Indication: Gingival Grafts
Addressing a critical unmet need in periodontal surgery with faster healing and significantly reduced post-operative pain.
Introducing ORD002
Our innovative delivery platform maintains therapeutic drug levels for 48-72 hours, eliminating the need for systemic administration while maximizing local efficacy and minimizing side effects.
How ORD002 Works
Electrospun Nanofibers: Biocompatible scaffold adheres to wound bed
Controlled Release: FTY720 delivered over 48-72 hours
Local Action: Targeted immune modulation at wound site
Faster Healing: Accelerated tissue regeneration
Reduced Pain: Improved patient comfort and outcomes
Our Regulatory Strategy
We're advancing ORD002 through the FDA 505(b)(2) regulatory pathway, leveraging existing safety data for fingolimod to accelerate development while demonstrating the unique benefits of our delivery system.
1st
In Class Drug-Device Combo
505(b)(2)
FDA Pathway
48-72h
Sustained Release
< 30 days
Drug Eluting Scaffold Dissolves
.png)